3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroendocrine Tumors
3
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
pembrolizumab
7
avelumab
6
Nivolumab
6
Specimen Handling
5
Magnetic Resonance Spectroscopy
4
Biopsy
4
Ipilimumab
3
prednylidene
2
lutetium Lu 177 dotatate
2
deltacortene
2
Radiosurgery
2
Prednisone
2
Immunoglobulin G
2
Cyclophosphamide
2
CTLA-4 Antigen
2
talimogene laherparepvec
1
sargramostim
1
lenvatinib
1
fludarabine phosphate
1
fludarabine
1
decitabine and cedazuridine drug combination
1
cemiplimab
1
atezolizumab
1
aldesleukin
1
X-Rays
1
Tacrolimus
1
Sirolimus
1
Saline Solution
1
Radiotherapy
1
MAPRE1 protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
90 days
×
Clear all
No trials found.